Tilray Brands, Inc. (TLRY)
USD 0.49
(-3.98%)
USD 0.49
(-3.98%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 | 251.35 Million USD | 22.45% |
| 2023 | 325.1 Million USD | -5.87% |
| 2022 | 345.37 Million USD | 80.12% |
| 2021 | 191.74 Million USD | 41.24% |
| 2020 | 135.75 Million CAD | 31.88% |
| 2019 | 102.94 Million CAD | 175.83% |
| 2018 | 37.31 Million CAD | 231.0% |
| 2017 | 11.27 Million CAD | 108.06% |
| 2016 | 5.41 Million CAD | -9.82% |
| 2015 | 6 Million CAD | 13155.14% |
| 2014 | 45.33 Thousand CAD | -53.98% |
| 2013 | 98.51 Thousand CAD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 FY | 251.35 Million USD | -22.68% |
| 2024 Q1 | 78.21 Million USD | -9.49% |
| 2024 Q2 | 82.1 Million USD | 4.97% |
| 2024 Q3 | 61.23 Million USD | -25.42% |
| 2024 Q4 | 83.89 Million USD | 37.01% |
| 2023 Q4 | 86.41 Million USD | 12.97% |
| 2023 Q3 | 76.49 Million USD | -8.97% |
| 2023 FY | 325.1 Million USD | -5.87% |
| 2023 Q1 | 81.87 Million USD | -11.69% |
| 2023 Q2 | 84.03 Million USD | 2.64% |
| 2022 Q3 | 84.31 Million USD | 6.28% |
| 2022 Q4 | 92.71 Million USD | 9.97% |
| 2022 FY | 345.37 Million USD | 80.12% |
| 2022 Q2 | 79.33 Million USD | -15.52% |
| 2022 Q1 | 93.9 Million USD | 49.22% |
| 2021 Q4 | 62.93 Million USD | -8.86% |
| 2021 Q1 | 39.36 Million CAD | 7.55% |
| 2021 Q2 | 46.3 Million CAD | 17.64% |
| 2021 Q3 | 69.05 Million CAD | 49.13% |
| 2021 FY | 191.74 Million USD | 41.24% |
| 2020 Q3 | 36.11 Million CAD | -0.97% |
| 2020 FY | 135.75 Million CAD | 31.88% |
| 2020 Q1 | 30.44 Million CAD | 5.07% |
| 2020 Q4 | 36.59 Million CAD | 1.34% |
| 2020 Q2 | 36.46 Million CAD | 19.77% |
| 2019 Q3 | 36.18 Million CAD | 81.88% |
| 2019 Q2 | 19.89 Million CAD | 11.13% |
| 2019 Q1 | 17.9 Million CAD | 7.89% |
| 2019 FY | 102.94 Million CAD | 175.83% |
| 2019 Q4 | 28.97 Million CAD | -19.91% |
| 2018 Q1 | 5.16 Million CAD | 92.3% |
| 2018 Q3 | 9.87 Million CAD | 72.86% |
| 2018 Q4 | 16.59 Million CAD | 68.11% |
| 2018 FY | 37.31 Million CAD | 231.0% |
| 2018 Q2 | 5.7 Million CAD | 10.53% |
| 2017 Q3 | 3.56 Million CAD | 31.72% |
| 2017 Q4 | 2.68 Million CAD | -24.61% |
| 2017 FY | 11.27 Million CAD | 108.06% |
| 2017 Q1 | 2.28 Million CAD | 29.73% |
| 2017 Q2 | 2.7 Million CAD | 18.27% |
| 2016 Q1 | 908.56 Thousand CAD | -3.37% |
| 2016 FY | 5.41 Million CAD | -9.82% |
| 2016 Q4 | 1.76 Million CAD | 21.47% |
| 2016 Q3 | 1.45 Million CAD | 8.78% |
| 2016 Q2 | 1.33 Million CAD | 46.87% |
| 2015 Q2 | 6482.23 CAD | -22.05% |
| 2015 Q1 | 8316.12 CAD | -86.85% |
| 2015 FY | 6 Million CAD | 13155.14% |
| 2015 Q4 | 940.24 Thousand CAD | -65.72% |
| 2015 Q3 | 2.74 Million CAD | 42213.04% |
| 2014 Q1 | 7855.65 CAD | 73.67% |
| 2014 Q3 | 47.23 Thousand CAD | 933.36% |
| 2014 Q4 | 63.26 Thousand CAD | 33.93% |
| 2014 FY | 45.33 Thousand CAD | -53.98% |
| 2014 Q2 | 4571.06 CAD | -41.81% |
| 2013 FY | 98.51 Thousand CAD | 0.0% |
| 2013 Q2 | 20.45 Thousand CAD | 49.81% |
| 2013 Q3 | 13.33 Thousand CAD | -34.84% |
| 2013 Q4 | 4523.23 CAD | -66.07% |
| 2013 Q1 | 13.65 Thousand CAD | -24.11% |
| 2012 Q2 | 3424.37 CAD | 0.0% |
| 2012 Q3 | 65.73 Thousand CAD | 1819.75% |
| 2012 Q4 | 17.99 Thousand CAD | -72.63% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Bright Green Corporation | 8.25 Million USD | -2945.691% |
| Alpha Teknova, Inc. | 45.85 Million USD | -448.108% |
| ANI Pharmaceuticals, Inc. | 195.98 Million USD | -28.254% |
| Aquestive Therapeutics, Inc. | 44.85 Million USD | -460.389% |
| Collegium Pharmaceutical, Inc. | 159.2 Million USD | -57.88% |
| Cosmos Health Inc. | 26.18 Million USD | -860.082% |
| Journey Medical Corporation | 54.59 Million USD | -360.411% |
| Embecta Corp. | 528.4 Million USD | 52.431% |
| Esperion Therapeutics, Inc. | 271.89 Million USD | 7.554% |
| Dynavax Technologies Corporation | 219.14 Million USD | -14.699% |
| Intra-Cellular Therapies, Inc. | 590 Million USD | 57.398% |
| Pacira BioSciences, Inc. | 326.37 Million USD | 22.986% |
| PainReform Ltd. | 9.58 Million USD | -2522.673% |
| Sunshine Biopharma, Inc. | 13.12 Million USD | -1815.178% |
| Sunshine Biopharma, Inc. | 13.12 Million USD | -1815.178% |
| SCYNEXIS, Inc. | 51.84 Million USD | -384.796% |
| Safety Shot Inc | 12.1 Million USD | -1975.668% |
| China SXT Pharmaceuticals, Inc. | 3.06 Million USD | -8089.691% |
| Procaps Group, S.A. | 199.47 Million USD | -26.008% |
| Theratechnologies Inc. | 72.75 Million USD | -245.479% |
| Harrow Health, Inc. | 89.97 Million USD | -179.369% |
| Sonoma Pharmaceuticals, Inc. | 9.44 Million USD | -2560.989% |
| Biofrontera Inc. | 39.95 Million USD | -529.037% |
| DURECT Corporation | 43.71 Million USD | -474.99% |
| Supernus Pharmaceuticals, Inc. | 529.01 Million USD | 52.485% |
| Cronos Group Inc. | 96.7 Million USD | -159.911% |
| OptiNose, Inc. | 85.1 Million USD | -195.36% |
| Ironwood Pharmaceuticals, Inc. | 232.12 Million USD | -8.286% |
| Kala Pharmaceuticals, Inc. | 39.15 Million USD | -541.987% |
| RedHill Biopharma Ltd. | -9.56 Million USD | 2728.982% |
| Organogenesis Holdings Inc. | 314.13 Million USD | 19.984% |
| Guardion Health Sciences, Inc. | 9.73 Million USD | -2483.098% |
| Cumberland Pharmaceuticals Inc. | 43.04 Million USD | -484.0% |
| Radius Health, Inc. | 265.92 Million USD | 5.48% |
| Universe Pharmaceuticals INC | 13.84 Million USD | -1715.913% |
| ProPhase Labs, Inc. | 37.85 Million USD | -564.052% |
| Phibro Animal Health Corporation | 260.29 Million USD | 3.435% |
| Procaps Group S.A. | 187.24 Million USD | -34.24% |
| Alvotech | 285.43 Million USD | 11.94% |
| TherapeuticsMD, Inc. | 9.82 Million USD | -2458.341% |
| Viatris Inc. | 5.96 Billion USD | 95.787% |
| Rockwell Medical, Inc. | 15.37 Million USD | -1534.949% |
| Aytu BioPharma, Inc. | 59.84 Million USD | -320.048% |
| SIGA Technologies, Inc. | 22.04 Million USD | -1040.302% |
| Lifecore Biomedical, Inc. | 49.03 Million USD | -412.576% |
| Shineco, Inc. | 17.94 Million USD | -1300.471% |
| PetIQ, Inc. | 192.72 Million USD | -30.423% |
| Regencell Bioscience Holdings Limited | 3.99 Million USD | -6197.878% |
| Incannex Healthcare Limited | 30.05 Million USD | -736.379% |
| Neurocrine Biosciences, Inc. | 1.59 Billion USD | 84.256% |
| Alimera Sciences, Inc. | 62.64 Million USD | -301.266% |
| Silver Spike Investment Corp. | 762.49 Thousand USD | -32865.198% |
| Assertio Holdings, Inc. | 368.58 Million USD | 31.805% |
| Shuttle Pharmaceuticals Holdings, Inc. | 5.88 Million USD | -4170.733% |
| Petros Pharmaceuticals, Inc. | 17.8 Million USD | -1311.441% |
| Clever Leaves Holdings Inc. | 21.16 Million USD | -1087.382% |
| Cyclo Therapeutics, Inc. | 21.04 Million USD | -1094.544% |
| Avadel Pharmaceuticals plc | 164.96 Million USD | -52.369% |
| Hempacco Co., Inc. | 7.59 Million USD | -3208.875% |
| Talphera, Inc. | 11.99 Million USD | -1995.69% |
| Alvotech | 285.43 Million USD | 11.94% |
| Eagle Pharmaceuticals, Inc. | 140.71 Million USD | -78.63% |
| Lantheus Holdings, Inc. | 344.9 Million USD | 27.122% |
| Currenc Group, Inc. | 24 Million USD | -947.23% |
| Kamada Ltd. | 45.42 Million USD | -453.333% |
| Indivior PLC | 911 Million USD | 72.409% |
| Evoke Pharma, Inc. | 12.4 Million USD | -1925.498% |
| Flora Growth Corp. | 10.57 Million USD | -2276.0% |
| Cyclo Therapeutics, Inc. | 21.04 Million USD | -1094.544% |
| Evolus, Inc. | 189.75 Million USD | -32.461% |
| HUTCHMED (China) Limited | 436.23 Million USD | 42.38% |
| Amphastar Pharmaceuticals, Inc. | 154.13 Million USD | -63.077% |
| Akanda Corp. | 3.48 Million USD | -7115.629% |